Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability

Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization

(2018) Tanya Camacho-Villegas et al.   Marine Drugs

In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization

(2018) Dalia Millán-Gómez et al.   Oncotarget

Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders

(2017) Doreen Könning et al.   Scientific Reports

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape

(2017) Evelien Moorkens et al.   Frontiers in Pharmacology

In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development

(2017) John Steven et al.   Frontiers in Immunology

Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development

(2017) Obinna C. Ubah et al.   Frontiers in Immunology

Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis

(2017) Marina Kovaleva et al.   Frontiers in Immunology

Nanobodies as therapeutics: big opportunities for small antibodies

(2016) Sophie Steeland et al.   DRUG DISCOVERY TODAY

Isolation of a pH-Sensitive IgNAR Variable Domain from a Yeast-Displayed, Histidine-Doped Master Library

(2016) Doreen Könning et al.   MARINE BIOTECHNOLOGY

VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry

(2016) Julien Häsler et al.   MOLECULAR IMMUNOLOGY

Coming-of-Age of Antibodies in Cancer Therapeutics

(2016) B. Vijayalakshmi Ayyar et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment

(2016) James R. Kintzing et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain

(2016) Selena G. Burgess et al.   Open Biology

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

(2015) William R. Strohl   BIODRUGS

The coming of age of engineered multivalent antibodies

(2015) Natalia Nuñez-Prado et al.   DRUG DISCOVERY TODAY

Analysis of Monoclonal Antibody Sequence and Post-translational Modifications by Time-controlled Proteolysis and Tandem Mass Spectrometry

(2015) Lichao Zhang et al.   MOLECULAR & CELLULAR PROTEOMICS

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

(2015) Maarten Van Roy et al.   ARTHRITIS RESEARCH & THERAPY

Shark Attack: High affinity binding proteins derived from shark vNAR domains by stepwise in vitro affinity maturation

(2014) Stefan Zielonka et al.   JOURNAL OF BIOTECHNOLOGY

Structural insights and biomedical potential of IgNAR scaffolds from sharks

(2014) Stefan Zielonka et al.   mAbs

A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display

(2014) Christian Schröter et al.   mAbs

Atypical Antigen Recognition Mode of a Shark Immunoglobulin New Antigen Receptor (IgNAR) Variable Domain Characterized by Humanization and Structural Analysis

(2013) Oleg V. Kovalenko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

B7h-expressing dendritic cells and plasma B cells mediate distinct outcomes of ICOS costimulation in T cell-dependent antibody responses

(2012) Kevin Larimore et al.   BMC IMMUNOLOGY

Variable domain antibodies specific for viral hemorrhagic septicemia virus (VHSV) selected from a randomized IgNAR phage display library

(2012) Maki Ohtani et al.   FISH & SHELLFISH IMMUNOLOGY

Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

(2012) Mischa R. Müller et al.   mAbs

Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody

(2011) Renae Walsh et al.   VIROLOGY

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

(2010) Tomoyuki Igawa et al.   NATURE BIOTECHNOLOGY

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

(2009) Roland E. Kontermann   BIODRUGS

Therapeutic antibodies: successes, limitations and hopes for the future

(2009) Patrick Chames et al.   BRITISH JOURNAL OF PHARMACOLOGY

Shark IgNAR antibody mimotopes target a murine immunoglobulin through extended CDR3 loop structures

(2007) David P. Simmons et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS